Postmenopausal estrogen therapy and cardiovascular disease

Barbara J. Fleming; Jerilynn C. Prior; David Atkins; David B. Maclean; Andrew Bostom; Meir J. Stampfer; Graham A. Colditz; Walter C. Willett; Joann E. Manson; Bernard Rosner; Frank E. Speizer; Charles H. Hennekens

doi:10.1056/NEJM199203053261012

Postmenopausal estrogen therapy and cardiovascular disease

Barbara J. Fleming, Jerilynn C. Prior, David Atkins, David B. Maclean, Andrew Bostom, Meir J. Stampfer, Graham A. Colditz, Walter C. Willett, Joann E. Manson, Bernard Rosner, Frank E. Speizer, Charles H. Hennekens

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: As the benefits of antiestrogen therapy in preventing or delaying the recurrence of breast cancer continue to be documented, as Stampfer et al. (Sept. 12 issue)* have done, more and more women will receive tamoxifen or other antiestrogen therapy for many years. There are also many who may not be receiving antiestrogen therapy, but who should certainly not be receiving estrogen replacement after estrogen-receptor—positive breast carcinoma. If estrogen replacement is protective against the development of osteoporosis and cardiovascular disease in postmenopausal women, what advice should we be giving to the increasingly large population of women who have.

Original language	English
Pages (from-to)	705-708
Number of pages	4
Journal	New England Journal of Medicine
Volume	326
Issue number	10
DOIs	https://doi.org/10.1056/NEJM199203053261012
State	Published - Mar 5 1992

Access to Document

10.1056/NEJM199203053261012

Cite this

@article{e0af50d73f244bf9916f7ec77664b93d,

title = "Postmenopausal estrogen therapy and cardiovascular disease",

abstract = "To the Editor: As the benefits of antiestrogen therapy in preventing or delaying the recurrence of breast cancer continue to be documented, as Stampfer et al. (Sept. 12 issue)* have done, more and more women will receive tamoxifen or other antiestrogen therapy for many years. There are also many who may not be receiving antiestrogen therapy, but who should certainly not be receiving estrogen replacement after estrogen-receptor—positive breast carcinoma. If estrogen replacement is protective against the development of osteoporosis and cardiovascular disease in postmenopausal women, what advice should we be giving to the increasingly large population of women who have.",

author = "Fleming, {Barbara J.} and Prior, {Jerilynn C.} and David Atkins and Maclean, {David B.} and Andrew Bostom and Stampfer, {Meir J.} and Colditz, {Graham A.} and Willett, {Walter C.} and Manson, {Joann E.} and Bernard Rosner and Speizer, {Frank E.} and Hennekens, {Charles H.}",

year = "1992",

month = mar,

day = "5",

doi = "10.1056/NEJM199203053261012",

language = "English",

volume = "326",

pages = "705--708",

journal = "New England Journal of Medicine",

issn = "0028-4793",

number = "10",

}

TY - JOUR

T1 - Postmenopausal estrogen therapy and cardiovascular disease

AU - Fleming, Barbara J.

AU - Prior, Jerilynn C.

AU - Atkins, David

AU - Maclean, David B.

AU - Bostom, Andrew

AU - Stampfer, Meir J.

AU - Colditz, Graham A.

AU - Willett, Walter C.

AU - Manson, Joann E.

AU - Rosner, Bernard

AU - Speizer, Frank E.

AU - Hennekens, Charles H.

PY - 1992/3/5

Y1 - 1992/3/5

N2 - To the Editor: As the benefits of antiestrogen therapy in preventing or delaying the recurrence of breast cancer continue to be documented, as Stampfer et al. (Sept. 12 issue)* have done, more and more women will receive tamoxifen or other antiestrogen therapy for many years. There are also many who may not be receiving antiestrogen therapy, but who should certainly not be receiving estrogen replacement after estrogen-receptor—positive breast carcinoma. If estrogen replacement is protective against the development of osteoporosis and cardiovascular disease in postmenopausal women, what advice should we be giving to the increasingly large population of women who have.

AB - To the Editor: As the benefits of antiestrogen therapy in preventing or delaying the recurrence of breast cancer continue to be documented, as Stampfer et al. (Sept. 12 issue)* have done, more and more women will receive tamoxifen or other antiestrogen therapy for many years. There are also many who may not be receiving antiestrogen therapy, but who should certainly not be receiving estrogen replacement after estrogen-receptor—positive breast carcinoma. If estrogen replacement is protective against the development of osteoporosis and cardiovascular disease in postmenopausal women, what advice should we be giving to the increasingly large population of women who have.

UR - http://www.scopus.com/inward/record.url?scp=1642505459&partnerID=8YFLogxK

U2 - 10.1056/NEJM199203053261012

DO - 10.1056/NEJM199203053261012

M3 - Letter

C2 - 1736111

AN - SCOPUS:1642505459

SN - 0028-4793

VL - 326

SP - 705

EP - 708

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 10

ER -

Postmenopausal estrogen therapy and cardiovascular disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this